An open‐label extension study to evaluate the long‐term safety, tolerability and efficacy of Marstacimab prophylaxis in severe (coagulation factor activity <1%) hemophilia A participants with or without inhibitors or moderately severe to severe hemophilia B participants (coagulation factor Activity ≤2%) with or without inhibitors

Project: Other project


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science